Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas
Public ClinicalTrials.gov record NCT03598998. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2 Study of Pembrolizumab Plus Pralatrexate for Treatment of Relapsed or Refractory Peripheral T-Cell Lymphomas
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This phase I/II trial studies the side effects and best dose of pralatrexate when given together with pembrolizumab and how well they work in treating patients with peripheral T-cell lymphomas that has come back after a period of improvement or has not responded to treatment. Pralatrexate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving pembrolizumab and pralatrexate may work better in treating patients with peripheral T-cell lymphomas.
Study identification
- NCT ID
- NCT03598998
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 13 participants
Conditions and interventions
Conditions
- Anaplastic Large Cell Lymphoma
- Nodal Peripheral T-Cell Lymphoma With TFH Phenotype
- Recurrent Anaplastic Large Cell Lymphoma
- Recurrent Angioimmunoblastic T-Cell Lymphoma
- Recurrent Enteropathy-Associated T-Cell Lymphoma
- Recurrent Follicular Lymphoma
- Recurrent Hepatosplenic T-Cell Lymphoma
- Recurrent Mature T- Cell and NK-Cell Non-Hodgkin Lymphoma
- Recurrent Monomorphic Epitheliotropic Intestinal T-cell Lymphoma
- Recurrent Mycosis Fungoides
- Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified
- Refractory Anaplastic Large Cell Lymphoma
- Refractory Angioimmunoblastic T-Cell Lymphoma
- Refractory Enteropathy-Associated T-Cell Lymphoma
- Refractory Follicular Lymphoma
- Refractory Hepatosplenic T-Cell Lymphoma
- Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
- Refractory Mycosis Fungoides
- Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified
- Subcutaneous Panniculitis-Like T-Cell Lymphoma
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 3, 2019
- Primary completion
- May 2, 2023
- Completion
- Feb 17, 2027
- Last update posted
- May 25, 2026
2019 – 2027
United States locations
- U.S. sites
- 3
- U.S. states
- 3
- U.S. cities
- 3
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope Medical Center | Duarte | California | 91010 | — |
| Emory University Hospital/Winship Cancer Institute | Atlanta | Georgia | 30322 | — |
| University of Nebraska Medical Center | Omaha | Nebraska | 68198 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03598998, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 25, 2026 · Synced Sep 9, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03598998 live on ClinicalTrials.gov.